Bryan Johnson· Author
I'm starting with DAC, weekly dosing of the long-acting version, and monitoring side effects closely. If they're intolerable, I'll switch to no-DAC + Ipamorelin, daily.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I'm starting with DAC, weekly dosing of the long-acting version, and monitoring side effects closely. If they're intolerable, I'll switch to no-DAC + Ipamorelin, daily.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
We are potentially starting with DAC at half dose, confirming signal, and assessing side effects. If not tolerable, we step down to no-DAC + ipamorelin, then sermorelin as fallback.